A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
- 17 August 1989
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 321 (7), 419-424
- https://doi.org/10.1056/nejm198908173210702
Abstract
To test the hypothesis that maximal androgen blockade improves the effectiveness of the treatment of prostatic cancer, we conducted a randomized, double-blind trial in patients with disseminated, previously untreated prostate cancer (stage D2). All 603 men received leuprolide, an analogue of gonadotropin-releasing hormone that inhibits the release of gonadotropins, in combination with either placebo or flutamide, a nonsteroidal antiandrogen that inhibits the binding of androgens to the cell nucleus.This publication has 28 references indexed in Scilit:
- The Endocrinology and Developmental Biology of the Prostate*Endocrine Reviews, 1987
- Long Term Treatment With Luteinising Hormone Releasing Hormone Agonists and Maintenance of Serum Testosterone to Castration ConcentrationsJournal of Urology, 1986
- Whole-Mount Autoradiography Study of DNA Synthetic Activity during Postnatal Development and Androgen-Induced Regeneration in the Mouse Prostate1Biology of Reproduction, 1986
- Establishment and characterization of seven dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancersThe Prostate, 1986
- Leuprolide versus Diethylstilbestrol for Metastatic Prostate CancerNew England Journal of Medicine, 1984
- The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancerThe Prostate, 1984
- A Confidence Interval for the Median Survival TimeBiometrics, 1982
- Hormonal Therapy of Prostatic CancerCancer, 1980
- Chemotherapy of advanced prostatic cancer Evaluation of response parametersUrology, 1976
- The veterans administration cooperative urological research group's studies of cancer of the prostateCancer, 1973